Brolucizumab Noninferior to Aflibercept for Diabetic Macular Edema

(MedPage Today) -- Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed.
In over 500 patients with DME, the best-corrected visual...

Source: MedPage Today Endocrinology - November 17, 2023 Category: Endocrinology Source Type: news